User login
Key clinical point: Cognitive behavioral therapy for targeted therapy-related fatigue (CBT-TTF) improved tyrosine kinase inhibitor (TKI)-related fatigue in patients with chronic-phase chronic myeloid leukemia (CML-CP).
Major finding: Patients receiving 18-week CBT-TTF vs. control reported improvements in physical (P = .023), mental (P = .015), and social activity (P = .001), along with enhanced cognitions including self-efficacy (P = .001), helplessness (P = .003), fatigue catastrophizing and focusing on symptoms (both P less than .001).
Study details: Findings are from secondary analysis of a trial including 36 adults with CML-CP treated with a TKI, who reported moderate to severe fatigue and were randomly allocated to receive either CBT-TTF (n=22) or waitlist control (n=14).
Disclosures: This study was funded by the National Cancer Institute. Some coinvestigators reported grants, consultancy, advisory, and speakers’ bureau memberships from various pharmaceutical companies.
Source: Hyland KA et al. Ann Behav Med. 2021 May 15. doi: 10.1093/abm/kaab035.
Key clinical point: Cognitive behavioral therapy for targeted therapy-related fatigue (CBT-TTF) improved tyrosine kinase inhibitor (TKI)-related fatigue in patients with chronic-phase chronic myeloid leukemia (CML-CP).
Major finding: Patients receiving 18-week CBT-TTF vs. control reported improvements in physical (P = .023), mental (P = .015), and social activity (P = .001), along with enhanced cognitions including self-efficacy (P = .001), helplessness (P = .003), fatigue catastrophizing and focusing on symptoms (both P less than .001).
Study details: Findings are from secondary analysis of a trial including 36 adults with CML-CP treated with a TKI, who reported moderate to severe fatigue and were randomly allocated to receive either CBT-TTF (n=22) or waitlist control (n=14).
Disclosures: This study was funded by the National Cancer Institute. Some coinvestigators reported grants, consultancy, advisory, and speakers’ bureau memberships from various pharmaceutical companies.
Source: Hyland KA et al. Ann Behav Med. 2021 May 15. doi: 10.1093/abm/kaab035.
Key clinical point: Cognitive behavioral therapy for targeted therapy-related fatigue (CBT-TTF) improved tyrosine kinase inhibitor (TKI)-related fatigue in patients with chronic-phase chronic myeloid leukemia (CML-CP).
Major finding: Patients receiving 18-week CBT-TTF vs. control reported improvements in physical (P = .023), mental (P = .015), and social activity (P = .001), along with enhanced cognitions including self-efficacy (P = .001), helplessness (P = .003), fatigue catastrophizing and focusing on symptoms (both P less than .001).
Study details: Findings are from secondary analysis of a trial including 36 adults with CML-CP treated with a TKI, who reported moderate to severe fatigue and were randomly allocated to receive either CBT-TTF (n=22) or waitlist control (n=14).
Disclosures: This study was funded by the National Cancer Institute. Some coinvestigators reported grants, consultancy, advisory, and speakers’ bureau memberships from various pharmaceutical companies.
Source: Hyland KA et al. Ann Behav Med. 2021 May 15. doi: 10.1093/abm/kaab035.